Liqitomic is a next-generation anatomical waste disposal technology developed by Sanondaf, a UK-based leader in advanced decontamination systems operating since 2014. With a minimum investment of US$250,000, the Liqitomic franchise offers a rare opportunity at the intersection of healthcare infrastructure, environmental compliance, and sustainable technology.
Liqitomic is a patented chemical dissolution system that safely neutralizes human and animal anatomical waste on-site — eliminating the need for traditional high-heat incineration, manual handling, and costly transportation. The technology has been validated through an 18-month scientific trial at a leading UK university and is now commercially operational.
Liqitomic is a compact, portable waste treatment unit designed for hospitals, veterinary clinics, research laboratories, and biomedical facilities. The system uses a proprietary chemical process to dissolve anatomical waste — including bone, tissue, and skin — within under one hour. The treated output is neutralized for standard discharge, meeting environmental and health-safety standards aligned with UN and WHO waste management guidelines.
The global medical waste management market continues to expand as healthcare systems generate increasing volumes of anatomical waste. Traditional incineration — the most common disposal method — carries significant drawbacks. It requires extreme heat, produces hazardous airborne emissions, demands costly centralized infrastructure, and involves extensive transportation of infectious materials.
Liqitomic addresses each of these pain points. The on-site treatment model eliminates transportation risks and reduces energy consumption dramatically compared to incineration. For investors, this positions the technology as both an environmental compliance solution and a cost-reduction tool for healthcare operators.
The Liqitomic franchise is structured as a services-based model. Operators deploy compact treatment units directly at client facilities — hospitals, veterinary clinics, universities, and research labs — and provide ongoing waste processing services. This creates a recurring revenue model anchored by long-term institutional contracts.
The asset-light nature of the operation keeps capital requirements manageable. Units are portable, installation is straightforward, and the chemical consumables are sourced through Sanondaf’s established supply chain. Franchisees benefit from Sanondaf’s decade-long track record in decontamination services across healthcare, aviation, education, and government sectors. For a broader look at the parent company’s franchise system, see the Sanondaf Franchise Overview 2026.
Several structural factors make Liqitomic compelling for master franchise investors evaluating Asia and MENA market entry. First, the regulatory tailwind is significant — governments worldwide are tightening medical waste disposal standards, creating mandatory demand for compliant solutions. Second, the competitive landscape is thin: very few franchise-ready alternatives exist in the anatomical waste category.
Third, the technology’s environmental profile aligns with the sustainability mandates increasingly required by hospital groups, university systems, and government procurement agencies. Operators who can offer a cleaner, more efficient disposal method hold a distinct competitive advantage in institutional sales cycles.
Liqitomic serves four primary verticals, each with distinct growth drivers:
Sanondaf already operates an international franchise network for its core disinfection services, providing the infrastructure and governance framework for Liqitomic’s global rollout. The company’s existing presence across multiple countries gives incoming Liqitomic franchisees access to established operational playbooks, training systems, and institutional sales channels. Strategic site selection using tools like GapMaps location intelligence can help operators identify high-density healthcare corridors for market entry.
For master franchise investors, Liqitomic represents a rare category — a science-validated, regulation-driven franchise opportunity in a market segment with virtually no branded competition and growing institutional demand. As healthcare infrastructure investment accelerates across Southeast Asia and the Middle East, operators who secure early territory rights stand to build durable, contract-based revenue streams in a market where compliance is non-negotiable.
Liqitomic is a chemical dissolution technology for anatomical waste disposal, developed by UK-based Sanondaf International. It provides an on-site alternative to traditional incineration for hospitals, veterinary clinics, and research facilities.
The minimum investment required for a Liqitomic franchise is US$250,000, according to VF Franchise Consulting’s brand listing.
Liqitomic franchise territories are available internationally. Contact the brand for specific market availability and territory structure.
This article was prepared by the VF Franchise Consulting editorial team — with over 30 years of experience in international franchise development, master franchise advisory, and brand expansion across Asia and the Middle East.
